P-gp-IN-30

P-gp-IN-30 (Compound 13) is a P-glycoprotein (P-gp) inhibitor by targeting YB-1. P-gp-IN-30 significantly enhances sensitivity to Paclitaxel by reducing total YB-1 and nucleus YB-1 protein expression, inhibiting the expression and function of downstream P-gp, further suppressing the efflux rate of Paclitaxel. P-gp-IN-30 potently inhibits tumor growth in A549/Taxol xenografts mice model with combination of Paclitaxel (HY-B0015) . P-gp-IN-30 can be used for non-small cell lung cancer (NSCLC) research[1].

Product Specifications

CAS Number

[2761881-65-4]

UNSPSC

12352005

Target

P-glycoprotein

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Cancer

Smiles

CCOC(C1([C@]2(C3=CC=CC=C3NC2=O)[C@H](C4=CC=CC=C4)[C@@H](C5=CC[C@@]6([H])[C@]5([H])[C@H](OC)OC=C6C(OC)=O)N1)C(OCC)=O)=O

Molecular Formula

C34H36N2O9

Molecular Weight

616.66

References & Citations

[1]Deng L, et al. Discovery of a novel Genipin derivative targeting YB-1 to enhance the P-glycoprotein-mediated paclitaxel sensitivity of paclitaxel-resistant non-small cell lung cancer. Eur J Med Chem. 2025 Jun 27;297:117910.